| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50242-0087-01 | 50242-0087 | ADO-Trastuzumab Emtansine | Kadcyla | 20.0 mg/mL, 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | HER2 | Intravenous | Feb 22, 2013 | In Use | |
| 65219-0670-01 | 65219-0670 | Denosumab | BOMYNTRA | 70.0 mg/mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 30, 2025 | In Use | |
| 00085-1242-01 | 00085-1242 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Jun 4, 1986 | Dec 4, 2010 | No Longer Used | ||
| 61755-0008-01 | 61755-0008 | cemiplimab-rwlc | LIBTAYO | 50.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Sep 28, 2018 | In Use | |
| 60505-4534-01 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | Mar 8, 2023 | In Use |
| 59572-0215-93 | 59572-0215 | Thalidomide | Thalomid | 150.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 20, 2007 | In Use | |
| 83077-0100-02 | 83077-0100 | Zenocutuzumab | BIZENGRI | 20.0 mg/mL | Immunotherapy | Bispecific Antibody | HER2, HER3 | Intravenous | Dec 4, 2024 | In Use | |
| 47781-0487-01 | 47781-0487 | Lenalidomide | LENALIDOMIDE | 20.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 6, 2023 | In Use | |
| 55513-0326-01 | 55513-0326 | rituximab-arrx | Riabni | 500.0 mg/50mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Jan 6, 2021 | In Use | |
| 43598-0516-01 | 43598-0516 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use | |
| 00085-1388-01 | 00085-1388 | Peginterferon alfa-2b | Sylatron | Immunotherapy | Cytokine | Interferon | Mar 29, 2011 | Jan 13, 2016 | No Longer Used | ||
| 55513-0207-21 | 55513-0207 | Bevacizumab-awwb | MVASI | 400.0 mg/16mL, 400.0 mg/16mL | Immunotherapy | Monoclonal Antibody | VEGFR | Intravenous | Jun 27, 2025 | In Use | |
| 00074-1044-01 | 00074-1044 | Telisotuzumab Vedotin | EMRELIS | 20.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | c-MET | Intravenous | May 14, 2025 | In Use | |
| 00078-0690-61 | 00078-0690 | Ofatumumab | Arzerra | 20.0 mg/mL | Immunotherapy | Monoclonal Antibody | CD20 | Intravenous | Feb 1, 2016 | In Use | |
| 63304-0042-01 | 63304-0042 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 4, 2023 | In Use | |
| 55513-0141-01 | 55513-0141 | trastuzumab-anns | Kanjinti | 150.0 mg/7.15mL | Immunotherapy | Monoclonal Antibody | HER2 | Intravenous | Oct 28, 2019 | In Use | |
| 72606-0059-01 | 72606-0059 | Denosumab-bmwo | Denosumab-BMWO | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Sep 10, 2025 | In Use | |
| 60219-1714-01 | 60219-1714 | Lenalidomide | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 00004-0352-39 | 00004-0352 | Peginterferon alfa-2a | Pegasys | Immunotherapy | Cytokine | Interferon | Oct 16, 2002 | Jul 31, 2015 | No Longer Used | ||
| 00008-0100-01 | 00008-0100 | Inotuzumab Ozogamicin | Besponsa | 0.25 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | Aug 18, 2017 | In Use | |
| 61314-0228-94 | 61314-0228 | Denosumab | WYOST | 120.0 mg/1.7mL | Immunotherapy | Monoclonal Antibody | RANKL | Subcutaneous | Jun 2, 2025 | In Use | |
| 00006-3026-02 | 00006-3026 | Pembrolizumab | Keytruda | 25.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Jan 15, 2015 | In Use | |
| 80739-0812-18 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec 12, 2022 | In Use | |
| 59572-0503-21 | 59572-0503 | Pomalidomide | Pomalyst | 3.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 60505-4534-02 | 60505-4534 | Lenalidomide | Lenalidomide | 10.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Sep 6, 2022 | In Use |
Found 11888 results — Export these results
Home